Search Results
162 items found for "high grade serous ovarian cancer"
- Ep 85 with Nicholas Holliday
discovery projects for both GPCR and non-GPCR targets, using its expertise in pharmacology to deliver high-quality
- Ep 59 with Dr. Nicola J. Smith
locked’, inaccessible receptors to well-characterized and understood ‘unlocked’ therapeutic targets with high-affinity
- GPCR Retreat 2023 - Part I
To that end, I'm grateful to be working alongside the very talented team at Orion who translate important Caron on the web UNC-Chapel Hill Department of Cell Biology and Physiology UNC Lineberger Comprehensive Cancer
- GPCRs and fibroblast heterogeneity in fibroblast-associated diseases
such as idiopathic pulmonary fibrosis, cardiac fibrosis, pancreatic fibrosis, hepatic fibrosis, and cancer
- A virally encoded GPCR drives glioblastoma through feed-forward activation of the SK1-S1P1 signaling axis
kinases AKT and CHK1 and the transcriptional regulators cMYC and STAT3 and by increasing the abundance of cancerous
- Unveiling Non-Canonical Functions for Gαq Signaling Pathways
(GRK2), a known regulator of Gq-GPCR signaling in HNSCC tumor progression (International Journal of Cancer
- Distinct sub-cellular signal propagation as a component of functional selectivity
of Biochemistry and Molecular Medicine and the CEO of the Institute for Research in Immunology and Cancer
- Dynamic Phosphoproteomics of BRS3 Activation Reveals the Hippo Signaling Pathway for Cell Migration
The lung cancer cell line H1299-BRS3 was treated with MK-5046, an agonist of BRS3, for different durations
- GPCR Courses
If you choose not to continue, you can cancel anytime before the trial ends without being charged. How do I cancel my membership? You can cancel your membership by following these steps: Go to My Account. Select the membership you want to cancel and click Cancel Subscription.
- Gallein, G protein βγ subunits inhibitor, suppresses the TGF-α-induced migration of hepatocellular carcinoma cells via inhibition of the c-Jun N-terminal kinase
Small molecules targeting the subunits of Gα and Gβγ have been developed as cancer therapeutics.
- Ep 78 with Dr. Stuart Maudsley
Maudsley was awarded a Howard Hughes Medical Institute Fellowship to train with Professor Robert Lefkowitz At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional
- "Have a nice weekend, and I'll see you tomorrow!": RAMP-interacting GPCR Pathways
Caron on the web UNC-Chapel Hill Department of Cell Biology and Physiology UNC Lineberger Comprehensive Cancer
- S1P Signaling Genes as Prominent Drivers of BCR-ABL1-Independent Imatinib Resistance and Six Herbal Compounds as Potential Drugs for Chronic Myeloid Leukemia
genes are promising therapeutic targets and plausible new innovation avenues to combat IM resistance in cancer
- Ep 43 with Dr. Stuart Maudsley
Maudsley was awarded a Howard Hughes Medical Institute Fellowship to train with Professor Robert Lefkowitz At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional
- Ep 72 with Dr. Stuart Maudsley
Maudsley was awarded a Howard Hughes Medical Institute Fellowship to train with Professor Robert Lefkowitz At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional
- Ep 151 with Dr GPCR Board
control cell signaling by protease-activated receptors (PARs) and the impact on vascular inflammation and cancer research has focused on PAR1, which has important functions in hemostasis, thrombosis, inflammation, and cancer
- Ep 109 with Dr. Katarina Nemec
technologies (FRET, BRET) that were used for functional screens with state-of-the-art microscopy and high
- Illuminating Functional Selectivity and Allosterism at GPCRs.
the generation of many intellectual property agreements and patents, and published his findings in high-impact
- Ep 114 with Dr. Robert F. Bruns
In 1988, he joined Lilly as a receptor biologist in charge of a high-throughput screening lab.
- Unbiased multitissue transcriptomic analysis reveals complex neuroendocrine regulatory networks mediated by spinal cord injury-induced immunodeficiency
sympathetic activity (blood pressure and catecholamine levels in plasma), were assessed in rats in the high-level in the GO term immunoregulation, indicating that splenic immune function was markedly impaired after high-level
- Evolutionary diversity of CXCL16-CXCR6: Convergent substitutions and recurrent gene loss in sauropsids
This axis is linked to diseases like HIV/SIV, cancer, and COVID-19. Previous studies of the CXCL16-CXCR6 axis found genetic variation among species but were limited to primates
- Ep 60 with Dr. Josephine (Pina) Cardarelli
The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers
- Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody
of regenerating liver 3 (PRL3) is a specific tumor antigen overexpressed in a broad range of adult cancer
- Prediction of survival and immunotherapy response by the combined classifier of G protein-coupled receptors and tumor microenvironment in melanoma
Chuanyuan Wei , Jianying Gu Tags G protein-coupled receptors , Immunotherapy , Melanoma , Multi-omics , Pan-cancer
- The binding mechanism of an anti-multiple myeloma antibody to the human GPRC5D homodimer
Its high expression on the surface of multiple myeloma cells has rendered it an attractive target for
- CCL5-producing migratory dendritic cells guide CCR5+ monocytes into the draining lymph nodes
Migratory monocytes expressed Ccr5, a high-affinity receptor for Ccl5.
- GPCR Retreat 2023 | Dr. GPCR Ecosystem
world-class and diverse GPCR scientists working in the arenas of structure and signaling, neuroscience, cancer
- Ep 50 with Dr. Thomas P. Sakmar
After moving to Rockefeller University with a Howard Hughes Medical Institute appointment, Tom advanced and Ping Chi , that a mutant of CYSLTR2 is a driver oncogene in uveal melanoma, the most common eye cancer